How we treat HER2-positive brain metastases

This publication has 22 references indexed in Scilit:

• Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
  New England Journal of Medicine, 2019
• The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis
  European Journal of Cancer, 2017
• Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
  Journal of Clinical Oncology, 2016
• Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
  Cancer Discovery, 2015
• CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
  Journal of Clinical Oncology, 2015
• Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery
  Neuro-Oncology, 2013
• CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)
  The Lancet Oncology, 2013
• Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype
  Breast Cancer Research and Treatment, 2012
• Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
  Clinical Cancer Research, 2009
• Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)
  Annals of Oncology, 2006